TY - JOUR
T1 - Smoothing membrane protein structure determination by initial upstream stage improvements
AU - Pedro, Augusto Quaresma
AU - Queiroz, João António
AU - Passarinha, Luís António
N1 - info:eu-repo/grantAgreement/FCT/5876/136013/PT#
info:eu-repo/grantAgreement/FCT/5876/147255/PT#
info:eu-repo/grantAgreement/FCT/5876-PPCDTI/128284/PT#
info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F81222%2F2011/PT#
Pest-C/SAU/UI709/2011
Project POCI-01-0145-FEDER-007491
UID/CTM/50011/2019
UID/Multi/04378/2019
POCI-01-0145-FEDER-030840
PY - 2019/7/20
Y1 - 2019/7/20
N2 - Membrane proteins (MP) constitute 20–30% of all proteins encoded by the genome of various organisms and perform a wide range of essential biological functions. However, despite they represent the largest class of protein drug targets, a relatively small number high-resolution 3D structures have been obtained yet. Membrane protein biogenesis is more complex than that of the soluble proteins and its recombinant biosynthesis has been a major drawback, thus delaying their further structural characterization. Indeed, the major limitation in structure determination of MP is the low yield achieved in recombinant expression, usually coupled to low functionality, pinpointing the optimization target in recombinant MP research. Recently, the growing attention that have been dedicated to the upstream stage of MP bioprocesses allowed great advances, permitting the evolution of the number of MP solved structures. In this review, we analyse and discuss effective solutions and technical advances at the level of the upstream stage using prokaryotic and eukaryotic organisms foreseeing an increase in expression yields of correctly folded MP and that may facilitate the determination of their three-dimensional structure. A section on techniques used to protein quality control and further structure determination of MP is also included. Lastly, a critical assessment of major factors contributing for a good decision-making process related to the upstream stage of MP is presented.
AB - Membrane proteins (MP) constitute 20–30% of all proteins encoded by the genome of various organisms and perform a wide range of essential biological functions. However, despite they represent the largest class of protein drug targets, a relatively small number high-resolution 3D structures have been obtained yet. Membrane protein biogenesis is more complex than that of the soluble proteins and its recombinant biosynthesis has been a major drawback, thus delaying their further structural characterization. Indeed, the major limitation in structure determination of MP is the low yield achieved in recombinant expression, usually coupled to low functionality, pinpointing the optimization target in recombinant MP research. Recently, the growing attention that have been dedicated to the upstream stage of MP bioprocesses allowed great advances, permitting the evolution of the number of MP solved structures. In this review, we analyse and discuss effective solutions and technical advances at the level of the upstream stage using prokaryotic and eukaryotic organisms foreseeing an increase in expression yields of correctly folded MP and that may facilitate the determination of their three-dimensional structure. A section on techniques used to protein quality control and further structure determination of MP is also included. Lastly, a critical assessment of major factors contributing for a good decision-making process related to the upstream stage of MP is presented.
KW - Codon usage
KW - Host
KW - Membrane protein
KW - Optimization
KW - Production
KW - Protein 3D-structure
KW - Quality control
KW - Structure determination
UR - http://www.scopus.com/inward/record.url?scp=85067671986&partnerID=8YFLogxK
U2 - 10.1007/s00253-019-09873-1
DO - 10.1007/s00253-019-09873-1
M3 - Review article
C2 - 31127356
AN - SCOPUS:85067671986
VL - 103
SP - 5483
EP - 5500
JO - Applied Microbiology and Biotechnology
JF - Applied Microbiology and Biotechnology
SN - 0175-7598
IS - 14
ER -